Shares of SMS Prescribed drugs Ltd surged 6% on 26 June after the corporate introduced receiving no observations from the US Meals and Drug Administration (USFDA).
The USFDA has completed its examination of the corporate’s Central Laboratory Analytical Providers, which is positioned in Gagillapur Village, Medchal Malkajgiri District, Hyderabad, Telangana. The inspection befell from 23 June to 25 June 2025 and resulted in zero Type 483 observations, in line with the enterprise.
The corporate is dedicated to reaching the best high quality requirements and to totally complying with CGMP and GLP rules in any respect manufacturing and analytical services, it acknowledged.
The “Central Laboratory Analytical Providers” is an impartial testing laboratory, and the power acquired its second profitable USFDA inspection, in line with the agency.
On 30 Might, the corporate acquired the Institution Inspection Report from the USFDA for the March 2025 inspection of its Energetic Pharmaceutical Ingredient (API) manufacturing facility in Bachupally, Hyderabad, Telangana.
The corporate reported a 17.5% enhance in Q4FY25 web revenue at Rs 20.32 crore over Rs 17.28 crore, whereas web income elevated by Rs 248.20 crore versus Rs 245.80 crore 12 months on 12 months.
On 23 September 2024 and seven April 2025, the inventory reached a 52-week excessive of Rs 398.00 and a low of Rs 175.00.
At 12:54 pm, the shares of SMS Prescribed drugs had been buying and selling 4.60% larger at Rs 250.10 on NSE.
Uncover the subsequent massive funding! Unicorn Alerts’ IPO screener helps you establish promising preliminary public choices. Obtain Unicorn Alerts and get forward of the curve! Signal Up Now & Discover Your Subsequent IPO Gem!
